{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/pelvic-inflammatory-disease/diagnosis/assessment/","result":{"pageContext":{"chapter":{"id":"6bef4b1a-5873-5e3c-a07f-a72df2163883","slug":"assessment","fullItemName":"Assessment","depth":2,"htmlHeader":"<!-- begin field 8962e9f3-41e3-4724-bcd7-85c691cc5346 --><h2>How should I assess a woman with suspected pelvic inflammatory disease?</h2><!-- end field 8962e9f3-41e3-4724-bcd7-85c691cc5346 -->","summary":"","htmlStringContent":"<!-- begin item 90230977-2754-4dba-bb57-1789acc302b6 --><!-- begin field 9be03ee8-e903-433f-8c86-81cd4ebed564 --><p><strong>A diagnosis of pelvic inflammatory disease (PID) should be made on clinical grounds. Do not delay making a diagnosis and initiating treatment whilst waiting for the results of laboratory tests. Negative swab results do not rule out a diagnosis of PID.</strong></p><ul><li><strong>Take a history.</strong><ul><li>Ask about the symptoms experienced (if any). Suspect PID if any of the following symptoms are present:<ul><li>Pelvic or lower abdominal pain (usually bilateral but can be unilateral).</li><li>Deep dyspareunia particularly of recent onset.</li><li>Abnormal vaginal bleeding (intermenstrual, postcoital, or 'breakthrough') which may be secondary to associated cervicitis and endometritis.</li><li>Abnormal vaginal or cervical discharge as a result of associated cervicitis, endometritis, or bacterial vaginosis. This is often very slight and may be transient, especially with chlamydial infection.</li><li>Right upper quadrant pain due to peri-hepatitis (<a class=\"topic-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/background-information/complications/\">Fitz&ndash;Hugh&ndash;Curtis syndrome</a>).</li><li>Secondary dysmenorrhoea.</li></ul></li><li>Ask about the possibility of pregnancy.</li></ul></li><li><strong>Examine the woman. </strong>Look for:<ul><li>Lower abdominal tenderness (usually bilateral).</li><li>Adnexal tenderness (with or without a palpable mass), cervical motion tenderness, or uterine tenderness (on bimanual vaginal examination).</li><li>Abnormal cervical or vaginal mucopurulent discharge (on speculum examination).</li><li>A fever of greater than 38°C, although the temperature is often normal.</li></ul></li><li><strong>Arrange <a class=\"topic-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/diagnosis/investigations/\">investigations</a> as appropriate.</strong> <ul><li>Consider referring the woman to a genito-urinary medicine (GUM) clinic or other local specialist sexual health service to facilitate screening for infections and for contact tracing.</li></ul></li></ul><!-- end field 9be03ee8-e903-433f-8c86-81cd4ebed564 --><!-- end item 90230977-2754-4dba-bb57-1789acc302b6 -->","topic":{"id":"9f0279a4-2834-5e5a-bcac-8bf82aa33bc3","topicId":"c3fb3eae-a416-4305-9bb7-f8c4a28827e3","topicName":"Pelvic inflammatory disease","slug":"pelvic-inflammatory-disease","lastRevised":"Last revised in June 2019","chapters":[{"id":"5f211e92-2994-512e-b182-200dcee7cfe5","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"1d99b28e-147a-50d9-b809-b2997de385cd","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"edca47ac-ad32-5cdc-b5b0-044c08354023","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"61747f80-342b-5eee-9f57-5585e2e266a1","slug":"changes","fullItemName":"Changes"},{"id":"34323845-1d0f-5dd2-9d12-aa4195ea061a","slug":"update","fullItemName":"Update"}]},{"id":"41aa50e1-c3d6-5af5-8d64-bf56566bcf4a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"5485b6d3-ad41-5a4f-8068-3927541fc840","slug":"goals","fullItemName":"Goals"},{"id":"8e512ac7-b08d-5db9-b36c-0b6bf6adeab6","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"16ee94a8-ef4e-5d73-9aab-3a7ad56481d0","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"00ebd775-876e-52d3-8917-e865f1ca24ac","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"00b18462-2317-5fa1-964d-480008f24d93","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"a76f3e2f-4836-5bfb-8b3d-65126afcd379","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b5957fa8-3b35-540f-93d4-a16fe133bcd7","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"7ffd6d91-45b2-5f09-8a72-1269c1cf4194","slug":"definition","fullItemName":"Definition"},{"id":"8d2eecb8-da49-56f0-b0f3-512e1ef7da78","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"cd56fa88-472b-5053-8750-7288cff96a45","slug":"incidence","fullItemName":"Incidence"},{"id":"eae17c05-1a5f-5d75-be7c-b0e30fbc5151","slug":"complications","fullItemName":"Complications"}]},{"id":"13e64b0f-f012-5f38-978c-906828fd01c0","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6bef4b1a-5873-5e3c-a07f-a72df2163883","slug":"assessment","fullItemName":"Assessment"},{"id":"44e7ae24-ecb6-5611-a376-e300900a9915","slug":"investigations","fullItemName":"Investigations"},{"id":"f2d53656-5ddd-5cac-a2f0-5155e3e4816f","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"04b9a20a-4646-577d-9db4-a82fad1f1122","fullItemName":"Management","slug":"management","subChapters":[{"id":"db64e69d-0dae-56cc-ac8c-111a4ae832f9","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"c9c97d1d-e768-53f0-8f37-0186133444ed","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"c6b38292-e76f-5f9e-b08f-9038f7a1e33c","slug":"azithromycin","fullItemName":"Azithromycin"},{"id":"33b4bf00-1e15-50d8-ae8e-cae48e64e869","slug":"ceftriaxone","fullItemName":"Ceftriaxone"},{"id":"07bec723-0e9e-5a18-9e33-37a6b08715b1","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"407d577d-6898-50ed-a49b-95ad0651ada7","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"631d3af6-f8a7-581f-9d98-a24412ab54f1","slug":"moxifloxacin","fullItemName":"Moxifloxacin"},{"id":"f5753d3f-d2cb-58c0-a3ba-9ea9ad6651ba","slug":"ofloxacin","fullItemName":"Ofloxacin"}]},{"id":"f7cbd9f8-3abb-50db-95c5-bb3b61731818","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"6b504e72-502e-54b1-8c90-a7bc3421bd9f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"c908da70-e8da-577d-aa14-2a477f0bc1cf","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"07e835ee-992a-5310-a2e1-6c64c3dcf57f","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"81326348-513f-5842-87bb-414706046cb1","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"0f235ae8-132c-5727-bb43-da1eaf2b8a7d","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"c0ba9a54-ce24-5b78-a3fa-c48701375f1c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"8c22c848-92a6-5535-b584-48002acef06e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"13e64b0f-f012-5f38-978c-906828fd01c0","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"898430ca-b0a6-5b59-ad7a-f13e3cdc5217","slug":"basis-for-recommendation-190","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field cd799a13-6dde-4cb1-9099-82826a625a5c --><h3>Basis for recommendation</h3><!-- end field cd799a13-6dde-4cb1-9099-82826a625a5c -->","summary":null,"htmlStringContent":"<!-- begin item 190f53d9-efe3-48eb-bac4-65accc518ac3 --><!-- begin field 89bee1ed-f5c3-4338-b8a6-93e240395efb --><p>These recommendations are based largely on the British Association for Sexual Health and HIV (BASHH) guideline <em>2018 United Kingdom national guideline for the management of pelvic inflammatory disease </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">BASHH, 2018</a>] and the <em>European guideline for the management of pelvic inflammatory disease </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">Ross, 2017</a>].</p><ul><li>Pelvic inflammatory disease (PID) may be symptomatic or asymptomatic. When present, clinical symptoms and signs lack sensitivity and specificity (the positive predictive value of a clinical diagnosis is 65–90% compared with laparoscopic diagnosis)<em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">Ross, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">BASHH, 2018</a>].</li><li>Expert opinion in the BASHH guideline is that<em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pelvic-inflammatory-disease/references/\">BASHH, 2018</a>]:<ul><li>A diagnosis of PID should be considered, and usually empirical antibiotic treatment offered, in any sexually active woman who has recent onset, lower abdominal pain associated with local tenderness on bimanual vaginal examination, in whom pregnancy has been excluded and no other cause for the pain has been identified.</li><li>The diagnosis of PID based only on positive examination findings, in the absence of lower abdominal pain, should only be made with caution.</li></ul></li></ul><!-- end field 89bee1ed-f5c3-4338-b8a6-93e240395efb --><!-- end item 190f53d9-efe3-48eb-bac4-65accc518ac3 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}